The board of directors of Town Health International Medical Group Limited announced that Mr. Hou Jun (Mr. Hou) has tendered his resignation as a non-executive Director with effect from 11 January 2024 as he would like to devote more time to focus on his other personal engagements. Mr. Hou has confirmed that he does not have any disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (Shareholders). The Board announced that Ms. Zhang Leidi (Ms. Zhang) has been appointed as a non-executive Director with effect from 12 January 2024.

Ms. Zhang Leidi, aged 43. Ms. Zhang obtained a master's degree in economics from Peking University in July 2003. Ms. Zhang has over 20 years of experience in equity investment and project management.

Ms. Zhang is currently the vice-president (presiding over the work) of China Life Private Equity Investment Company Limited (China Life Private Equity), and serves as a director and/or supervisor in several subsidiaries of China Life Private Equity. As at the date of this announcement, China Life Private Equity is a wholly-owned subsidiary of China Life Insurance (Group) Company a substantial Shareholder Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (Stock Exchange)). Ms. Zhang worked in Roland Berger Strategy Consultants from July 2003 to February 2010, where she successively worked as consultant, senior consultant and project manager.

From March 2011 to September 2011, she worked as a part-time consultant in Roland Berger Strategy Consultants. From October 2011 to September 2016, Ms. Zhang worked in China Life Investment Holdings Co. Ltd. where she successively, worked as senior manager, investment director and senior investment director of the direct investment department.

Since October 2016, Ms. Zhang has worked in China Life Private Equity, successively working as managing director, chairperson of management committee and vice-president (presiding over the work). From March 2019 to April 2022, Ms. Zhang was a director of Bloomage Biotechnology Corporation Limited; from March 2020 to May 2023, Ms. Zhang was a director of Nanjing Vazyme Biotech Co. Ltd.; from September 2020 to August 2023, Ms. Zhang was a director of Shanghai United Imaging Healthcare Co.

Ltd.; and since November 2022, Ms. Zhang has been a non-executive director of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Ms. Zhang will enter into a letter of appointment with the Company as a non-executive Director for a term commencing from 12 January 2024 to 31 December 2024, and she will be subject to rotation and re-election at general meeting of the Company in accordance with the bye-laws of the Company. Ms. Zhang will not be entitled to any remuneration from the Company in her capacity as a non-executive Director.

The Board announces that with effect from 12 January 2024: Mr. Yu Xuezhong, an independent non-executive Director, has resigned as a member of the audit committee of the Board (Audit Committee); Dr. Xu Weiguo, an independent non-executive Director, has resigned as a member of the remuneration committee of the Board (Remuneration Committee); Mr. Liu Yang, a non-executive Director, has been appointed as a member of each of the Audit Committee and the Remuneration Committee; Mr. Chan Wai Kan, an independent non-executive Director, has been appointed as member of the Remuneration Committee; Mr. Cheung Ka Ming, an independent non-executive Director, has been appointed as a member of the Audit Committee; and Mr. Tsui Wing Cheong Sammy, an independent non-executive Director, has been appointed as a member of the nomination committee of the Board (Nomination Committee).